Clinical Research Directory
Browse clinical research sites, groups, and studies.
Vericiguat for Heart Failure With Reduced Ejection Fraction After Myocardial Infarction
Sponsor: Qilu Hospital of Shandong University
Summary
The effects of vericiguat on cardiac remodeling in patients with chronic stable heart failure after myocardial infarction have not been reported. This project aims to clarify the efficacy and safety of vericiguat in patients with chronic heart failure after myocardial infarction. Patients with chronic stable heart failure with reduced ejection fraction after myocardial infarction in the electronic medical records of Qilu Hospital of Shandong University will be selected and divided into two groups: the treatment group received vericiguat in addition to conventional treatment and the control group received conventional treatment only. After 12-month treatment, the effects of vericiguat on cardiac remodeling and function and cardiovascular adverse events will be evaluated. The results are helpful to provide a new treatment strategy for chronic heart failure after myocardial infarction.
Official title: Vericiguat for Ventricular Remodeling in Patients With Heart Failure With Reduced Ejection Fraction After Myocardial Infarction
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
210
Start Date
2025-01-01
Completion Date
2027-12-31
Last Updated
2024-12-04
Healthy Volunteers
No
Interventions
Vericiguat Oral Tablet [Verquvo]
Vericiguat in addition to conventional treatment
Prescription Drugs
Conventional treatment only
Locations (3)
Qilu Hospital of Shandong University
Jinan, Shandong, China
Central Hospital Affiliated to Shandong First Medical University
Jinan, Shandong, China
The First Affiliated Hospital of Shandong First Medical University/Shandong Province Qianfoshan Hospital
Jinan, Shandong, China